City

Clinical trials near Beijing, China

Active studies with a listed research site in Beijing, China.

123active studies

58recruiting now

21countries represented

195largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

Peripheral Arterial DiseaseCondition

Orforglipron, PlaceboTreatment

Argentina, Australia161 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07223593See eligibility →

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

Overweight, ObesityCondition

Eloralintide, PlaceboTreatment

Argentina, China157 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07282600See eligibility →

Recruiting nowPhase 3

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

Osteoarthritis, Overweight or ObesityCondition

Eloralintide, PlaceboTreatment

Argentina, Belgium152 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07353931See eligibility →

Recruiting nowPhase 3

A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

Urinary Incontinence,StressCondition

Orforglipron, PlaceboTreatment

Canada, China136 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07202884See eligibility →

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Sleep Apnea, Obstructive, ObesityCondition

Eloralintide, PlaceboTreatment

Australia, Brazil115 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07369011See eligibility →

Recruiting nowPhase 3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

OsteoarthritisCondition

Orforglipron, PlaceboTreatment

Canada, China88 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07153471See eligibility →

Recruiting nowPhase 2

Phase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus (T2DM)Condition

MWN109 1, MWN109 2Treatment

China1 locations

Shanghai Minwei Biotechnology Co., LtdSponsor

Updated 2026-09-03 · NCT07801820See eligibility →

Recruiting nowPhase 3

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

Overweight, ObesityCondition

Cagrilintide, SemaglutideTreatment

Australia, Austria121 locations

Novo Nordisk A/SSponsor

Updated 2026-08-31 · NCT07253285See eligibility →

Recruiting nowPhase 1, Phase 2

A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity

Overweight and/or Obesity, Weight ManagementCondition

ecnoglutide tablets, placebo with matching dosageTreatment

China1 locations

Hangzhou Sciwind Biosciences Co., Ltd.Sponsor

Updated 2026-08-28 · NCT07243171See eligibility →

Recruiting nowNot applicable

OverStitch NXT Endoscopic Suture System

Weight LossCondition

OverStitch NXT Endoscopic Suture SystemTreatment

China1 locations

Boston Scientific CorporationSponsor

Updated 2026-08-28 · NCT07276815See eligibility →

Recruiting nowPhase 3

A Study of XW003 in Obese Participants With Obstructive Sleep Apnea But Not Receive Positive Airway Pressure Therapy

OSA - Obstructive Sleep Apnea, ObesityCondition

XW003 injection, placebo with matching volumeTreatment

China1 locations

Hangzhou Sciwind Biosciences Co., Ltd.Sponsor

Updated 2026-08-28 · NCT07387094See eligibility →

Recruiting nowPhase 3

A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus

Obesity, OverweightCondition

Elecoglipron, PlaceboTreatment

China, Hong Kong49 locations

AstraZenecaSponsor

Updated 2026-08-27 · NCT07775404See eligibility →

Recruiting nowPhase 3

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

Obesity or OverweightCondition

Placebo, EnicepatideTreatment

Argentina, Australia195 locations

Hoffmann-La RocheSponsor

Updated 2026-08-14 · NCT07351045See eligibility →

Recruiting nowPhase 3

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

Obesity or Overweight, Type 2 Diabetes MellitusCondition

Placebo, EnicepatideTreatment

Argentina, Australia193 locations

Hoffmann-La RocheSponsor

Updated 2026-08-14 · NCT07351058See eligibility →

Recruiting nowPhase 3

A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes

Obesity, OverweightCondition

Enicepatide, PlaceboTreatment

China18 locations

Hoffmann-La RocheSponsor

Updated 2026-08-13 · NCT07670416See eligibility →

Recruiting nowPhase 3

A Study of DA-302168S in Participants With Overweight/Obesity

Overweight and ObesityCondition

DA-302168S, DA-302168STreatment

China1 locations

Chendu DIAO Pharmaceutical Group CO., LTD.Sponsor

Updated 2026-08-06 · NCT07629544See eligibility →

Recruiting nowPhase 3

AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

Obesity, OverweightCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Australia, China92 locations

Novo Nordisk A/SSponsor

Updated 2026-08-04 · NCT07571109See eligibility →

Recruiting nowPhase 1

Phase Ib Study of Efsubaglutide Alfa Injection in Obese Adolescents

Adolescence ObesityCondition

Efsubaglutide Alfa 5 mg QW, Efsubaglutide Alfa 10 mg QWTreatment

China5 locations

Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.Sponsor

Updated 2026-07-30 · NCT07693426See eligibility →

Recruiting nowNot applicable

Bariatric Surgery Combined With GLP-1RA: A Multicenter Study.

ObesityCondition

BS-GLP1RA group, BS groupTreatment

China7 locations

China-Japan Friendship HospitalSponsor

Updated 2026-07-29 · NCT07732738See eligibility →

Recruiting nowPhase 3

AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

Obesity, OverweightCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Australia, China80 locations

Novo Nordisk A/SSponsor

Updated 2026-07-13 · NCT07571005See eligibility →

Recruiting nowNot applicable

GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity

ObesityCondition

LSG-Semaglutide group, LSG-Mazdutide groupTreatment

China1 locations

China-Japan Friendship HospitalSponsor

Updated 2026-06-08 · NCT07633639See eligibility →

Recruiting nowPhase 3

Phase III Study of HRS-7535 for Hypertension With Overweight or Obesity

Hypertension With Overweight or ObesityCondition

HRS-7535, PlaceboTreatment

China2 locations

Shandong Suncadia Medicine Co., Ltd.Sponsor

Updated 2026-06-05 · NCT07528027See eligibility →

Recruiting nowNot applicable

Smartwatch-based Intervention for Cardiovascular Health (SWITCH)

Prehypertension, Borderline DyslipidemiaCondition

Smartwatch-Based Multi-Faceted Behavioral Intervention Model Led by Exercise and Dietary Interventions, Supported by Primary Medical Staff, Along with the Distribution of Health Education Manuals, Face-to-face health education sessionsTreatment

China3 locations

Beijing Anzhen HospitalSponsor

Updated 2026-05-14 · NCT07372729See eligibility →

Recruiting nowPhase 1, Phase 2

Bariatric Surgery Combined With GLP-1 Receptor Agonists Study

ObesityCondition

BS-GLP group, BS groupTreatment

China1 locations

China-Japan Friendship HospitalSponsor

Updated 2026-04-23 · NCT07336862See eligibility →

Recruiting nowPhase 1

The Safety, Tolerability, and Pharmacokinetics of of SYH9017 in Chinese Participants With Overweight and Obesity

Overweight or ObesityCondition

SYH9017, PlaceboTreatment

China1 locations

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.Sponsor

Updated 2026-04-06 · NCT06830343See eligibility →

Recruiting nowNot applicable

iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs Optimized Lifestyle Intervention for Weight Loss

Overweight and/or Obesity, Metabolic SyndromeCondition

Endoscopic Radial Compression Gastroplasty, Optimized Lifestyle Intervention (OLI)Treatment

China2 locations

Liu YanSponsor

Updated 2026-03-13 · NCT07237750See eligibility →

Recruiting nowNot applicable

Combination of COMBO Endoscopy Oropharyngeal Airway and HFNC Oxygenation in Sedated Gastrointestinal Endoscopy for Morbidly Obese Patients

Hypoxemia, Esophageal CancerCondition

COMBO Endoscopy Oropharyngeal Airway with High-Flow Nasal Cannula Oxygenation, High-Flow Nasal Cannula OxygenationTreatment

China5 locations

Zhejiang UniversitySponsor

Updated 2026-03-11 · NCT07175155See eligibility →

Recruiting nowPhase 3

Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss

Overweight or ObesityCondition

GZR18 injection, PlaceboTreatment

China2 locations

Gan & Lee Pharmaceuticals.Sponsor

Updated 2026-03-11 · NCT07292441See eligibility →

Recruiting nowPhase 3

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy

Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP TherapyCondition

HRS9531, PlaceboTreatment

China1 locations

Fujian Shengdi Pharmaceutical Co., Ltd.Sponsor

Updated 2026-01-26 · NCT06994650See eligibility →

Recruiting nowNot applicable

Study on the Safety and Efficacy of Domestic Single-Port Robot-Assisted Metabolic Bariatric Surgery.

Obesity, Robot SurgeryCondition

Robot-assisted single-port bariatric surgeryTreatment

China1 locations

China-Japan Friendship HospitalSponsor

Updated 2026-01-13 · NCT07335731See eligibility →

Recruiting nowNot applicable

Comparative Study on the Effect of Diet Interventions on Weight Loss in Overweight Endometrial Cancer Patients Undergoing Fertility-sparing Treatment

Endometrium CancerCondition

Multi-Professional Guided '5+2' Intermittent Fasting, Low-energy Balanced DietTreatment

China1 locations

Peking University People's HospitalSponsor

Updated 2026-01-06 · NCT07318727See eligibility →

Recruiting nowPhase 2

Study on the Efficacy and Safety of HRS-7535 in Patients With Mild Decrease in Ejection Fraction/Preserved Ejection Fraction Heart Failure and Obesity

Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and ObesityCondition

HRS-7535 tablet, HRS-7535 tablet placeboTreatment

China1 locations

Shandong Suncadia Medicine Co., Ltd.Sponsor

Updated 2025-12-29 · NCT06820099See eligibility →

Recruiting nowPhase 1

Study on Gastric Emptying Effect and Drug-Drug Interactions of GZR18 Injection

Obesity or OverweightCondition

GZR18 injection,digoxin tablets, rosuvastatin calcium tablets and warfarin sodium tabletsTreatment

China1 locations

Gan & Lee Pharmaceuticals.Sponsor

Updated 2025-12-12 · NCT07128888See eligibility →

Recruiting nowPhase 2

UBT251 Injection Phase II Clinical Study (CKD)

Obesity &Amp; Overweight, Chronic Kidney DiseaseCondition

UBT251, UBT251Treatment

China1 locations

The United Bio-Technology (Hengqin) Co., Ltd.Sponsor

Updated 2025-11-25 · NCT07134335See eligibility →

Recruiting nowPhase 3

Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects

Obesity/Overweight in AdultCondition

GZR18, Semaglutide(Wegovy® )Treatment

China1 locations

Gan & Lee Pharmaceuticals.Sponsor

Updated 2025-11-25 · NCT07150975See eligibility →

Recruiting nowNot applicable

Peking University Birth Cohort in Weifang (PKUBC-WF)

Health Problems in Pregnancy, Pregnancy OutcomesCondition

No InterventionsTreatment

China1 locations

Peking UniversitySponsor

Updated 2025-11-24 · NCT06234332See eligibility →

Recruiting nowPhase 1

Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Renal Impairment and Normal Renal Function

Obesity/OverweightCondition

GZR18 injectionTreatment

China1 locations

Gan & Lee Pharmaceuticals.Sponsor

Updated 2025-11-21 · NCT07141030See eligibility →

Recruiting nowNot applicable

Study on Supplement of Intravenous Ferric Derisomaltose to Prevent Anemia and Improve the Quality of Life in Obese Patients With Iron Deficiency.

Obesity, AnemiaCondition

Iron Isomaltoside injection, Physiological saline solution (as placebo)Treatment

China1 locations

China-Japan Friendship HospitalSponsor

Updated 2025-11-19 · NCT07236788See eligibility →

Recruiting nowPhase 3

A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity

Bstructive Sleep Apnea (OSA) and ObesityCondition

HRS9531, HRS9531placeboTreatment

China1 locations

Fujian Shengdi Pharmaceutical Co., Ltd.Sponsor

Updated 2025-11-17 · NCT06974851See eligibility →

Recruiting nowPhase 2

A Study of BGM0504 in Participants With Obesity

ObesityCondition

BGM0504, TirzepatideTreatment

China1 locations

BrightGene Bio-Medical Technology Co., Ltd.Sponsor

Updated 2025-10-28 · NCT06911203See eligibility →

Recruiting nowPhase 1

Phase I Study of XTL6001 Injection in Healthy and Obese Subjects

Weight Management in Adult Patients With Obesity or OverweightCondition

XTL6001, PlaceboTreatment

China1 locations

Shanghai Xitaili Biomedicine Technology co., Ltd.Sponsor

Updated 2025-10-03 · NCT07205432See eligibility →

Recruiting nowNot applicable

Weight Management in Overweight Endometrial Cancer Patients Undergoing Fertility-sparing Treatment

Endometrium CancerCondition

Weight management--diet, Weight management--exerciseTreatment

China1 locations

Peking University People's HospitalSponsor

Updated 2025-09-03 · NCT06169449See eligibility →

Recruiting nowPhase 1

Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Liver Insufficiency and Normal Liver Function

Obesity/OverweightCondition

GZR18 injection, GZR18 injectionTreatment

China1 locations

Gan & Lee Pharmaceuticals.Sponsor

Updated 2025-08-27 · NCT07144098See eligibility →

Recruiting nowNot applicable

Acupuncture for Prediabetes With Combined Obesity

Obesity, Abdominal ObesityCondition

Acupuncture, Sham acupunctureTreatment

China1 locations

Guang'anmen Hospital of China Academy of Chinese Medical SciencesSponsor

Updated 2025-08-22 · NCT06359418See eligibility →

Recruiting nowNot applicable

China Health Big Data

Osteoporosis, ObesityCondition

Intervention not listedTreatment

China6 locations

Beijing Jishuitan HospitalSponsor

Updated 2025-08-17 · NCT03699228See eligibility →

Recruiting nowNot applicable

Radiomics of Intra-abdominal and Subcutaneous Adipose Tissue Predict the Efficacy of Bariatric Surgery (RISABS)

Obesity, Type 2 Diabetes MellitusCondition

Intervention not listedTreatment

China1 locations

China-Japan Friendship HospitalSponsor

Updated 2025-08-03 · NCT06169033See eligibility →

Recruiting nowPhase 3

Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are Overweight

ObesityCondition

RAY1225, PlaceboTreatment

China1 locations

Guangdong Raynovent Biotech Co., LtdSponsor

Updated 2025-07-17 · NCT06893016See eligibility →

Recruiting nowPhase 2

A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity

Obesity, Heart Failure With Preserved Ejection Fraction (HFPEF)Condition

placebo, IBI362Treatment

China1 locations

Innovent Biologics (Suzhou) Co. Ltd.Sponsor

Updated 2025-07-11 · NCT06862908See eligibility →

Recruiting nowPhase 3

A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2

Sleep Apnea, ObstructiveCondition

placebo, IBI362Treatment

China1 locations

Innovent Biologics (Suzhou) Co. Ltd.Sponsor

Updated 2025-06-29 · NCT06931028See eligibility →

Recruiting nowNot applicable

Mobile Applet for Weight Management in Obese Heart Failure Patients

Heart Failure, Overweight and ObesityCondition

Full usage of diet management app group and with the full usage of an intelligent weight scale, Limited usage of diet management app group and with the limited usage of an intelligent weight scaleTreatment

China26 locations

Heart Health Research CenterSponsor

Updated 2025-06-27 · NCT06455878See eligibility →

Recruiting nowPhase 3

Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients

Obesity ControlCondition

HDM1702, Wegovy ®Treatment

China1 locations

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Sponsor

Updated 2025-06-25 · NCT07036172See eligibility →

Recruiting nowNot applicable

App and Body Fat Scale in the Management of Overweight Patients

Schizophrenia, Bipolar DisorderCondition

Effectiveness and Feasibility of Self-Monitoring for Weight Management in Individuals with Mental Disorders Using Digital Intervention ("SWIM" trial)Treatment

China1 locations

Capital Medical UniversitySponsor

Updated 2025-06-05 · NCT05866107See eligibility →

Recruiting nowPhase 4

Liraglutide Treatment in Obese Infertile PCOS Women

PCOS, ObesityCondition

Liraglutide and metformin, MetforminTreatment

China3 locations

Peking University Third HospitalSponsor

Updated 2025-05-29 · NCT06742710See eligibility →

Recruiting nowNot applicable

Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study

Sacubitril/Valsartan, HypertensionCondition

Sacubitril / Valsartan Oral Tablet [Entresto], ACEI/ARBTreatment

China1 locations

Beijing Friendship HospitalSponsor

Updated 2025-02-13 · NCT05498675See eligibility →

Recruiting nowPhase 3

A Study of BGM0504 in Participants with Type 2 Diabetes

Type 2 Diabetes Mellitus (T2DM)Condition

Drug: 5 mg BGM0504 Administered SC, Drug:10 mg BGM0504 Administered SCTreatment

China1 locations

BrightGene Bio-Medical Technology Co., Ltd.Sponsor

Updated 2025-02-07 · NCT06716216See eligibility →

Recruiting nowNot applicable

Thread Embedding Acupuncture Therapy for Weight Loss

Obesity and OverweightCondition

Thread embedding acupuncture, Sham thread embedding acupunctureTreatment

China1 locations

Beijing Hospital of Traditional Chinese MedicineSponsor

Updated 2025-01-16 · NCT06653530See eligibility →

Recruiting nowPhase 3

A Study of BGM0504 Injection in Participants with Obesity or Overweight

Overweight or ObesityCondition

5 mg BGM0504 injection, 10 mg BGM0504 injection administered subcutaneously (SC) once a weekTreatment

China1 locations

BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd.Sponsor

Updated 2024-11-26 · NCT06704581See eligibility →

Recruiting nowNot applicable

Risk Factors and Multiomics Study of Chronic Kidney Disease Caused by Metabolic Diseases

Chronic Kidney Diseases, HypertensionCondition

BiomarkersTreatment

China1 locations

Peking Union Medical College HospitalSponsor

Updated 2022-08-16 · NCT05476627See eligibility →

Opening soonPhase 3

A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity

Obesity, OverweightCondition

Berobenatide, PlaceboTreatment

China33 locations

PfizerSponsor

Updated 2026-09-04 · NCT07792954See eligibility →

Opening soonPhase 1

A Clinical Trial of TQF3250 Capsules in Overweight/Obese Trial Participants With Poor Weight Control Through Simple Lifestyle Intervention

Overweight/ObesityCondition

TQF3250 capsules, TQF3250 placeboTreatment

China10 locations

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Sponsor

Updated 2026-09-01 · NCT07798284See eligibility →

This page shows the first 60 studies. Use the full search to filter all matches.

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.

Clinical trials near Beijing, China

Current studies

Related cities